Want to see GB:VAL full AI Analyst Report?
VAL Stock Chart & Stats
0.40 p
>-0.01 p(-0.67%)
At close: 4:00 PM EST
0.40 p
>-0.01 p(-0.67%)
Day’s Range― - ―
52-Week Range0.15 p - 0.85 p
Previous CloseN/A
Volume1.58M
Average Volume (3M)1.10M
Market Cap
£2.11M
Enterprise Value180.41K
Total Cash (Recent Filing)£791.61K
Total Debt (Recent Filing)£1.40K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume510,641
30 Day Avg. Volume1,099,814
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt materially reduces financial risk and interest burden, preserving flexibility to fund R&D or structure partnerships. For an early-stage biotech this durable capital structure lowers insolvency risk and improves ability to secure staged, non-dilutive funding or collaborations.
Licensing-based Business ModelA partnership and out-licensing model aligns with early-stage asset development, avoiding large commercial capex and enabling milestone/royalty monetization. If programs progress, this durable model can scale revenues through partner-funded trials and downstream royalties.
Lean, Focused Development TeamA small, focused team and clear therapeutic focus support nimble decision-making and lower fixed costs, preserving runway. Lean operations can accelerate program go/no-go choices and make the company an efficient, acquisable partner for larger pharma over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows the company cannot self-fund development. This structural cash burn forces recurring external financing, raising dilution risk and potentially limiting ability to advance multiple programs or meet clinical timelines without partner funding.
Eroding Balance SheetDeclining shareholders' equity and assets reflect accumulated losses that weaken funding capacity and negotiation leverage. A smaller balance sheet constrains the firm's ability to self-finance trials, reduces optionality, and may force more dilutive or disadvantageous deals.
Minimal, Declining RevenueTiny and shrinking revenues with negative gross profit indicate little commercial traction or meaningful licensing cashflows. This structural lack of recurring income prolongs dependency on external capital and increases execution risk for advancing programs to value-creating milestones.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.15 p and its highest was 0.85 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £2.11M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Sep 08, 2026 which is in 68 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Jun 22, 2026. The company reported -0.002 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002 p.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.002 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.108%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Options Prices
Currently, No data available
---